This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Diagnosis  • Oncology  • Pathology & Laboratory Medicine  • Alert me on articles by topic

Bridget M. Kuehn

JAMA. 2005;293:783-785.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Scientists from 10 US research institutions are embarking on an ambitious project to speed the discovery of clinically useful protein biomarkers for use in diagnosing cancers at the earliest and most treatable stages.

With $13.4 million in federal funding, two groups of biotechnology and cancer research institutions are trying to develop a standard set of tools and resources for proteomics research that will help speed the discovery of clinically useful cancer biomarkers. The emerging field of proteomics, which catalogs and analyses the proteins in a cell or organism, also holds promise as a means of personalizing medicine.

Scientists are working to identify and characterize proteins in blood serum with the goal of discovering peptides and proteins that might prove to be useful cancer biomarkers. (Photo credit: Pacific Northwest National Laboratory)

Despite its promise, the field of clinical proteomics is still in its infancy, and is likely to . . . [Full Text of this Article]

BOTTLENECK TO THE CLINIC

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Technologies to shape the future: proteomics applications in anesthesiology and critical care medicine.
Atkins and Johansson
Anesth. Analg. 2006;102:1207-1216.
ABSTRACT | FULL TEXT